

Ref no: From: Date: Subject: 235261120 Commercial 26/11/20 Migraine

## **REQUEST & RESPONSE**

- Q1. Please provide the number of patients treated (for any condition) in the last 4 months with:
- Ajovy (fremanezumab)
- Aimovig (erenumab)
- Emgality (galcanezumab)

## St Helens and Knowsley Teaching Hospitals NHS Trust do not hold this information in the requested format.

- Q2. How many of these patients were treated as part of a free or nominal charge scheme with:
- Ajovy (fremanezumab)
- Aimovig (erenumab)
- Emgality (galcanezumab)

## St Helens and Knowsley Teaching Hospitals NHS Trust do not hold this information in the requested format.

- Q3. How many patients have you treated in the last 4 months for:
- Any type of migraine
- Chronic migraine (15+ headache days per month).
- Episodic migraine (4+ headache days per month)

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.

Q4. Please provide the number of migraine patients treated in the last 4 months with Botulinum Toxin (i.e. Botox, Dysport, Xeomin).

Of the 478 unique patients, there were no patients coded with Botulinum Toxin.

Q5. In case you do not treat chronic or episodic migraine, can you please tell us which hospital or trust you refer these patients to?

There is a pathway to GP Assessment Unit for migraine patients with a view to not admitting as patients are then referred to outpatient neurology. The Trust have visiting consultants who do outpatient clinics at STHK from The Walton Centre.